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Abstract
Introduction—Minimum important difference (MID) estimates the minimum degree of change
in an instrument's score that correlates with a patient's subjective sense of improvement. We aimed
to determine the MID for the International Consultation on Incontinence Questionnaire-Urinary
Incontinence Short Form (ICIQ-UI SF) using both anchor based and distribution based methods
derived using data from the Trial of Midurethral Slings (TOMUS).
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Materials and Methods—Instruments for the anchor-based analyses included the Urogenital
Distress Inventory (UDI), Incontinence Impact Questionnaire (IIQ), Patient Global Impression of
improvement (PGI-I), incontinence episodes (IE) on 7-day bladder diary and satisfaction with
surgical results. After confirming moderate correlation (r ≥0.3) of ICIQ-UI SF and each anchor,
MIDs were determined by calculating the difference between the mean instrument scores for
individuals with the smallest amount of improvement and with no change. The distribution-based
method of MID assessment was applied using effect sizes of 0.2 and 0.5 SD (small to medium
effects). Triangulation was used to examine these multiple MID values in order to converge on a
small range of values.
Results—Anchor-based MIDs range from -4.5 to -5.7 at 12 months and from -3.1 to 4.3 at 24
months. Distribution-based MID values were lower. Triangulation analysis supports a MID of -5
at 12 months and -4 at 24 months.
Corresponding Author Larry T. Sirls, MD 31157 Woodward Avenue Royal Oak, Michigan 48073 Phone 248 336 3388 Fax 248 336
3190 Lsirls@mac.com.
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Conclusion—The recommended MIDs for ICIQ-UI SF are -5 at 12 months and -4 at 24 months.
In surgical patients, ICIQ-UI SF score changes that meet these thresholds can be considered
clinically meaningful.
Keywords
Minimum Important Difference; ICIQ-UI SF; Urinary incontinence; Quality of life; Midurethral
sling

Introduction

NIH-PA Author Manuscript

Determination of disease-specific distress and impact on quality of life (QOL) are important
parts of the assessment of patients prior to and after an intervention for stress urinary
incontinence. As a part of this assessment in the Trial of Midurethral Slings (TOMUS)
study1, the International Consultation on Incontinence Questionnaire Urinary Incontinence
Short Form (ICIQ-UI SF) was used2,3. The ICIQ-UI SF is a validated, robust measure of
impact found to be sensitive to change with intervention. The minimal important difference
is “the smallest difference in score in the domain of interest which patients perceive as
beneficial and which would mandate, in the absence of troublesome side-effects and
excessive cost, a change in the patient's management”4. The smallest change in a
questionnaire score that is found to correlate with meaningful symptom improvement is
called the minimally important difference (MID) or, sometimes, the minimal clinically
important difference (MCID). MID's are important because small numerical differences in
mean questionnaire scores might be statistically significant when large sample sizes are
used, but statistical significance may not be clinically significant. Knowledge of this
measure helps one discern whether observed within-group or between-group statistically
significant differences in questionnaire scores meet a threshold that is clinically significant
or meaningful.
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The ICIQ-UI SF is a brief 3-scored and 1 un-scored measure to assess the prevalence,
frequency and volume of urine leakage as well as its impact on QOL. It demonstrates good
construct validity and reliability and high correlation with the Sandvik Severity score3,5.
Using outcome measures of the TOMUS study and applying both anchor-based and
distribution-based methods of calculation, the purpose of this paper was to determine the
MID of the ICIQ-UI SF6. MID may vary over time with certain chronic conditions, we
evaluate MID estimates for two important time points commonly used in evaluating stress
incontinence treatment outcomes. This information should help in the interpretation of data
obtained from the treatment of urinary incontinence and in planning of future studies.

METHODS
Data from the Trial of Midurethral Slings (TOMUS) conducted by the Urinary Incontinence
Treatment Network (UITN) were used for these analyses. The NIDDK-sponsored UITN
consists of urologists and urogynecologists from nine clinical centers and a data
coordinating center. TOMUS was a multi-center randomized surgical trial comparing the
efficacy and morbidity of retropubic and transobturator mid-urethral sling procedures for
treatment of stress urinary incontinence (SUI). Women diagnosed with predominant SUI by
Neurourol Urodyn. Author manuscript; available in PMC 2015 March 01.
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self-reported symptoms for at least three months and a positive stress test at a bladder
volume ≤ 300 mL and who desired surgical therapy for the treatment of SUI were eligible.
Five hundred ninety seven (597) subjects were randomized in the TOMUS trial, with an
average age of 53 +/- 11 years. The majority (n-473; 79%) were Non-Hispanic White, and
3% were Non-Hispanic Black. Subjects who completed both baseline and 12-month
evaluations (84%) and those who completed both baseline and 24-month evaluations (75%)
comprise the analytical sample.
There is no “gold standard” methodology of estimating the MID or achieving the
meaningfulness of clinical trial results based on patient reported outcomes7. However, two
commonly used methods are anchor-based methods that examine the relationship between
scores on the target instrument and some independent measure, and distribution-based
methods resorting to the statistical characteristics of the obtained scores8. We used both
methods to determine MIDs for the ICIQ-UI SF.
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Anchor-based MID is determined by calculating the difference between the mean instrument
score for those individuals with the smallest amount of improvement and the mean
instrument score of those individuals with no change8. For all anchor based analyses,
Kendall's rank correlation coefficients or Spearman correlation coefficients were first
calculated to determine whether the instrument and anchors were at least moderately
correlated (r ≥0.3) [4,5,7,8]. Only if this criterion was met did we proceed with the
calculation of an anchor-based MID.
For this analysis, the anchors included the Urogenital Distress Inventory (UDI),
Incontinence Impact Questionnaire (IIQ), Incontinence episodes (IE) on the 7-day bladder
diary, Patient Global Impression of Improvement (PGI-I) and Satisfaction with surgical
results.
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For the UDI and IIQ anchors, we compared the difference in ICIQ-UI SF scores between
patients with a ≥75% reduction to those with no change. Using criteria similar to those used
to calculate the MIDs in the UITN BE-DRI Study8, we determined the mean change in
ICIQ-UI SF scores by the 7-day bladder diary as: “worse” ≥25% increase in IE; “no change”
= a change in any direction between 0 and 24%; and “better” ≥25% decrease in IE. We
defined the MID as the difference in ICIQ-UI SF scores between those who were “better”
and those who demonstrated “no change”. Since this 25% reduction was arbitrarily chosen,
we also analyzed ≥75% reduction in IE on the 7-day diary9. The PGI-I scale is a self-rated
assessment of change after treatment with 7 response levels ranging from “very much
worse” to “very much better”10. We used the difference in mean ICIQ-UI SF scores between
patients reporting “very much better” and all other responses. Satisfaction with surgical
results was measured with the question: “How satisfied or dissatisfied are you with the result
of bladder surgery related to the urine leakage?: --completely satisfied, mostly satisfied,
neutral, mostly dissatisfied or completely dissatisfied”. We used the difference in mean
ICIQ-UI SF scores between patients reporting “somewhat satisfied (completely satisfied or
mostly satisfied or neutral)” and those reporting “not at all satisfied (mostly dissatisfied or
completely dissatisfied)”.
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The distribution-based method of MID assessment was applied using an effect size of 0.2
and 0.5 SD4,7,10,11. The effect size is calculated by dividing the difference between the
baseline and follow-up scores by the standard deviation at baseline12 and represents
individual change in terms of the number of baseline standard deviations. Per Cohen's rule, a
value of 0.20 is a small effect, 0.50 is a medium effect, and 0.80 is a large effect. This
approach is widely understood and central to many psychometric indices8.
The application of multiple methods to determine the MID for ICIQ-UI SF in a specific
patient population will result in a range of values for the MID. Triangulation was used to
examine these multiple values in order to converge on a small range of values. The different
MID estimates were graphed to visually depict the range of estimates11. MID estimates and
95% CIs of each anchor- and distribution-based approach were then compared based on
recommendations of Revicki et al.11.

RESULTS
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The ICIQ-UI SF, UDI, and IIQ scores improved post-treatment at 12 months and at 24
months. Likewise, the number of IE ascertained from the bladder diaries declined after
treatment. There were 349 women (69%) and 294 women (65%) who reported that they
were “very much better” on the PGII at 12 months and 24 months, respectively. Four
hundred sixty (88%) and 403 (87%) women also reported that they were “Mostly satisfied”
or “Completely satisfied” with the result of bladder surgery related to the urine leakage at 12
months and 24 months, respectively (Table 1).
The ICIQ-UI SF met the a priori criterion for using an anchor-based approach (Kendall's
rank correlation coefficients or Spearman correlation coefficients (r) of ≥ 0.3) for
determining the MID at 12 months and 24 months for all anchors (UDI, IIQ, IE, PGI-I, and
Satisfaction with surgical results) (Table 2).
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The mean change in ICIQ-UI SF scores at 12 months and 24 months for the anchors by
response levels, as well as the ICIQ-UI SF MID for these anchors, are presented in Table 3.
The MID (95% CI) of the changes in ICIQUI SF using UDI as the anchor varied from -5.1
(-5.9, -4.2) to -4.2 (-5.0, -3.4) at 12 months and 24 months, respectively. A similar variation
was found in the MID (95% CI) of the change in ICIQ-UI SF from the IIQ: -5.7 (-6.8, -4.6)
at 12 months and -4.2 (-5.2, -3.1) at 24 months. The MID (95% CI) using IE with a 25%
reduction cut-point as the anchor were -4.8 (-7.5, -2.1) and -3.1 (-5.7, -0.5) at 12 months and
24 month, respectively. When the alternate cut-points were used for IE (75% reduction), the
MID value was consistent with all others: -4.5 (-5.8, -3.1) at 12 months and -4.1 (-5.3, -3.0)
at 24 months. The MID (95% CI) based on the PGI-I and Satisfaction measures were -4.8
(-5.6, -3.9) and -5.2 (-6.6, -3.7) at 12 months and -4.2 (-5.1, -3.4) and -4.3 (-5.8, -2.8) at 24
months, respectively.
In Table 4, distribution-based MIDs are presented for the ICIQ-UI SF using 0.2 SD, and 0.5
SD. When using the distribution-based methods, the MID values were lower than those
obtained using anchor-based methods (Table 3).
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Figure 1 shows the comparison of MID estimates with 95% CIs from the anchor and
distribution-based approaches.
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Discussion
Our study provides MID estimates for two important time points commonly recommended
in stress incontinence treatment studies. Studies have suggested that MID may vary over
time with certain chronic conditions8. The anchor-based MID at 12 months (-5) is slightly
different from that at 24 months (-4) and provides a more refined threshold for investigators
who will use the ICIQ-UI SF in future studies.
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Researchers are increasingly incorporating patient-reported outcomes (PROs) as research
outcomes. These MID values complement, but do not replace PROs as the MID is a
population based observation, an individual woman's perspective may not correlate with
these changes. A known limitation of anchor-based methods that rely on global ratings,
particularly over longer periods of time, is that they are susceptible to recall bias and may
reflect the patient's current life experience or mood13. Nonetheless, the FDA established
guidelines for patient reported outcome measures that recommend the use of anchor-based
methods to establish empiric evidence for responder data.14
In this analysis, we determined anchor-based methods using four patient-reported measures
(UDI, IIQ, PGI-I, satisfaction) and one objective measure of severity (IE), resulting in a
range of MID values. However, we recognized the clinical utility of a single value. A
strength of this analysis is the use of triangulation, a systematic method to integrate the
results and arrive on a single value for each of the two assessment time periods.11,15 MIDs
from clinical anchors that reflect patient-rated variables like a global rating of change are
given the most weight. The global rating of change provides the single best measure of the
significance of change from an individual perspective7 and take into account more
information that may affect QOL than other clinical tools.
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Distribution–based methods to determine MID are based on the statistical characteristics of
the obtained sample and can help support anchor-based methods or provide a MID when
anchor-based methods are not available.11 An effect size of 0.5 (change of ½ SD) is likely to
be clinically significant across different patient reported questionnaires.11 Advantages of
distribution-based methods are that they provide a means for establishing change beyond
some level of random variation, and provide a common metric that has equivalent meaning
across measures, populations, and studies. Disadvantages of distribution-based methods are
that there are few agreed-upon benchmarks for establishing clinically significant
improvement and they do not in themselves provide a good sense of the clinical relevance of
the change.
Klotkin showed that distribution-based and anchor-based methods were consistent with
moderate impairment but were markedly different for mild or severe impairment16. The fact
that our surgical cohort had high pre-operative scores with large post-treatment change may
explain why our distribution-based MIDs were lower than the anchor-based MIDs. The mild
to moderate treatment effects observed in a non-surgical SUI trial may result in lower MIDs.
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However, as SUI is commonly treated surgically, we believe these values are useful for
surgical researchers. Dyer showed that a non-surgical cohort of UUI patients had a higher
MID for the Urogenital Distress Inventory than did a SUI surgical cohort.8,10 This may
reflect the higher QOL impact of UUI reflected in higher baseline UDI scores than in SUI
patients, and that patient perception of improvement required more clinical improvement for
UUI than for SUI patients.
Other strengths of this study include the prospectively collected data from a large, multicenter, surgical cohort characterized with validated clinical anchors used to establish the
ICIQ-UI SF MID. Individual researchers will need to determine whether it is appropriate to
generalize these MID to non-surgical or non-SUI populations.

Conclusions
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The recommended MIDs for the ICIQ-UI SF in a population of women with stress
predominant UI are -5 for assessment at 12 months and -4 for assessment at 24 months.
Although data from surgical cohorts may overestimate MID because of uniformly high preoperative scores without significant variability that have a large improvement in score after
treatment, statistically significant changes (improvements) in ICIQ-UI SF scores that meet
these time-specific thresholds can be considered clinically meaningful.
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Figure 1.

Minimally important differences (MID) for the International Consultation on Incontinence
Questionnaire (ICIQ) using both Anchor and Distribution-Based Methods.
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Table 1
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Instrument (ICIQ-UI SF) and Anchors at Baseline, 12 Months, and 24 Months
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Baseline

12 month

24 month

N=581 13.2 ± 4.1

N=516 2.8 ± 3.5

N=460 3.3 ± 3.5

UDI (range 0-300)

N=597 134.6 ± 45.5

N=527 25.2 ± 35.2

N=469 30.7 ± 37.3

IIQ (range 0-400)

N=597 151.5 ± 97.4

N=527 20.1 ± 47.5

N=468 23.1 ± 50.3

N=593 3.3 ± 3.0

N=490 0.4 ± 1.2

N=435 0.5 ± 1.4

1: Very much better

---

349 (68.7%)

294 (64.6%)

2: Much better

---

110 (21.7%)

112 (24.6%)

3: A little better

---

34 (6.7%)

31 (6.8%)

4: No change

---

7 (1.4%)

15 (3.3%)

5: A little worse

---

4 (0.8%)

1 (0.2%)

6: Much worse

---

3 (0.6%)

1 (0.2%)

7: Very much worse

---

1 (0.2%)

1 (0.2%)

Completely satisfied

---

346 (66.2%)

257 (55.6%)

Mostly satisfied

---

114 (21.8%)

146 (31.6%)

Neutral

---

15 (2.9%)

17 (3.7%)

Mostly dissatisfied

---

27 (5.2%)

23 (5.0%)

Completely dissatisfied

---

21 (4.0%)

19 (4.1%)

ICIQ-UI SF (range 0-21)

Incontinence episodes(IE) per day
PGI-I

Satisfaction (Urine leakage)
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Table 2
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Correlation between Instrument (ICIQ-UI SF) and Anchors
ΔUDI

ΔIIQ

ΔIE

PGI-I

Satisfaction

At 12 month
        Δ ICIQ-UI SF

*

0.49

*

0.49

*

0.40

**

0.37

**

0.33

At 24 month
        Δ ICIQ-UI SF

*

0.48

*

0.44

*

0.40

**

0.36

**

0.33

*

Correlations using Spearman rho.

**

Correlations using Kendall's tau.
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Table 3
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Anchor-based measures and the mean change in ICIQ-UI SF by each category and the anchor-based MID (and
95% CI) at 12 months and 24 months.
Anchor measure

N

12 months

n

24 months

Improved (≥ 75% decrease)

366

−11.7 (4.37)

289

−11.5 (4.16)

No change (0 to 75%)

137

−6.68 (4.75)

159

−7.24 (4.33)

1

−1.73 (---)

1

1.53 (---)

% Change in UDI75%, Mean (SD)

Worse (≥ 75% increase)
MID (95% CI) for ICIQ-UI SF using Change in UDI

−5.1 (−5.9, −4.2)

**

−4.2 (−5.0, −3.4)

% Change in IIQ75%, Mean (SD)
Improved (≥ 75% decrease)

414

−11.4 (4.36)

356

−10.8 (4.20)

No change (0 to 75%)

80

−5.67 (5.17)

88

−6.64 (5.12)

Worse (≥ 75% increase)

5

−2.23 (4.36)

0

-----

MID (95% CI) for ICIQ-UI SF using Change in IIQ

−5.7 (−6.8, −4.6)

**

−4.2 (−5.2, −3.1)
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% Change in IE25%, Mean (SD)
Improved (≥ 25% decrease)

427

−10.9 (4.69)

375

−10.2 (4.54)

No change (0 to 25%)

12

−6.11 (4.60)

12

−7.13 (4.63)

Worse (≥ 25% increase)

8

−1.04 (5.26)

14

−6.02 (4.36)

MID (95% CI) for ICIQ-UI SF using % Change in IE

−4.8 (−7.5, −2.1)

**

−3.1 (−5.7, −0.5)

% Change in IE75%, Mean (SD)
Improved (≥ 75% decrease)

389

−11.2 (4.56)

336

−10.7 (4.40)

No change (0 to 75%)

53

−6.71 (5.23)

60

−6.51 (3.89)

Worse (≥ 75% increase)

5

−3.17 (5.51)

5

−6.99 (7.41)

MID (95% CI) for ICIQ-UI SF using % Change in IE

−4.5 (−5.8, −3.1)

**

−4.1 (−5.3, −3.0)

PGI-I (2 categories), Mean (SD)
Very much better (1)

336

−11.9 (4.35)

284

−11.4 (4.27)

Others (2-7)

152

−7.11 (4.87)

155

−7.21 (4.29)

−4.8 (−5.6, −3.9)

†

MID (95% CI) for ICIQ-UI SF using PGI-I

−4.2 (−5.1, −3.4)
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Follow-up Satisfaction, Mean (SD)
Somewhat satisfied = (Completely satisfied or Mostly satisfied or Neutral)

454

Not at all satisfied = (Mostly dissatisfied or Completely dissatisfied)

46

‡

MID (95% CI) for ICIQ-UI SF using Satisfaction

−10.8 (4.65)

404

−5.64 (6.06)

38

−5.2 (−6.6, −3.7)

−10.3 (4.43)
−6.01 (5.71)
−4.3 (−5.8, −2.8)

**

MID was computed based on the difference in ICIQ-UI SF mean change between “Improved” group and “No change” group.

†

MID was computed based on the difference in ICIQ-UI SF mean change between “Very much better” group and “Others” group.

‡

MID was computed based on the difference in ICIQ-UI SF mean change between “Somewhat satisfied” group and “Not at all satisfied” group.
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Table 4
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Distribution-based MID for the ICIQ-UI SF
Effect Size

Δ ICIQ-UI SF

0.2 SD*

−0.82

0.5 SD*

−2.05

Baseline SD (=4.1) was used to compute the effect size.
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